Related Experiment Video
Updated: Dec 2, 2025
04:32
Sound Source Localization Testing in Single-sided Deafness Following Bone Conduction Intervention
Published on: December 20, 2024
673
Patient-reported long-term benefit with an active transcutaneous bone-conduction device
Julia Hundertpfund1, Jens Eduard Meyer1,2, Attila Óvári1,2,3
1Asklepios Medical School, Semmelweis University, Hamburg, Germany.
Plos One
|November 2, 2020
Summary
Active transcutaneous bone-conduction devices significantly improve hearing quality of life and patient satisfaction long-term. These devices offer effective hearing rehabilitation with minimal adverse events and improved audiological outcomes.
Area of Science:
- Audiology
- Biomedical Engineering
- Otolaryngology
Background:
- Conductive or mixed hearing loss impacts quality of life.
- Bone-conduction devices offer an alternative rehabilitation approach.
- Long-term outcomes of active transcutaneous bone-conduction devices require further evaluation.
Purpose of the Study:
- To assess long-term hearing-related quality of life, patient satisfaction, and device usage.
- To report on adverse events and audiological outcomes as secondary measures.
Main Methods:
- Retrospective, mono-centric cohort analysis of 16 adult patients.
- Utilized Speech, Spatial and Qualities of Hearing Scale (SSQ12-B) and Audio Processor Satisfaction Questionnaire (APSQ).
- Collected audiological data and adverse event information from patient charts.
Main Results:
- Significant improvements in hearing-related quality of life across all SSQ12-B subscales (mean 2.95 points).
- High patient satisfaction reported (mean APSQ score 8.8).
- Improved word recognition (75.9% gain) and lowered speech reception threshold (35.1 dB reduction); 8 minor adverse events resolved.
Conclusions:
- Active transcutaneous bone-conduction devices provide sustained benefits in hearing quality of life and satisfaction.
- The device demonstrates effectiveness and comfort in hearing rehabilitation.
- Positive audiological outcomes and a low adverse event rate support its use.
